02.06.2012 • NewsTevaPharmaceuticalsgenerics

Teva Chairman Buys 1 Million Shares of Drugmaker

The chairman of Teva Pharmaceutical Industries has purchased 1 million U.S.-listed shares of the world's largest generic drugmaker, the company said on Friday.

Board Chairman Phillip Frost bought the shares on Wednesday, the first day of trading on the New York Stock Exchange. Previously, the U.S.-listed shares of the Israeli company traded on Nasdaq.

Frost bought shares at prices ranging from $37.82 to $39.57, according to the company. The shares were up 0.5% at $39.38 on Friday, moving into positive territory after Teva announced Frost's purchase.

"This investment is simply a reflection of the strength of my conviction regarding Teva's bright future," Frost said in a company-released statement.

Teva, which has a market value of about $38 billion, recently installed Jeremy Levin, a former executive at Bristol-Myers Squibb, as its new chief executive.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.